| Previous Close | 32.76 |
| Open | 32.76 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 32.70 - 33.22 |
| 52 Week Range | 29.83 - 35.38 |
| Volume | 13,452,221 |
| Avg. Volume | 18,315,874 |
| Market Cap | 197.15B |
| Beta | 1.05 |
| PE Ratio (TTM) | 27.90 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.91%) |
| Ex-Dividend Date | 2017-08-02 |
| 1y Target Est | N/A |
- Reuters•1 hour ago
India grants Pfizer patent on pneumonia vaccine in blow to aid group
India has granted Pfizer Inc a patent for its powerful pneumonia vaccine Prevenar 13, in a blow to some health groups that said this would put the treatment out of reach of thousands in poorer nations. The decision by India's patent office bars other companies from making cheaper copies of the vaccine and allows Pfizer to exclusively sell it in India until 2026.
- Motley Fool•12 hours ago
What's Next for Bristol-Myers Squibb After Its Opdivo Setback?
Mixed results for a study with Opdivo in treating first-line kidney cancer give reasons for concern. But how worried should investors really be?
- Zacks•17 hours ago
Immunomedics' Progress in Phase II Cancer Study Encouraging
Immunomedics, Inc. (IMMU) announced encouraging interim results from a phase II study on its cancer candidate, labetuzumab govitecan. Shares were up 7% on Monday in response.
